Comparison of Pteridine Normalization Methods in Urine for Detection of Bladder Cancer
Piotr Kośliński,
Robert Pluskota,
Katarzyna Mądra-Gackowska,
Marcin Gackowski,
Michał J. Markuszewski,
Kornelia Kędziora-Kornatowska,
Marcin Koba
Affiliations
Piotr Kośliński
Department of Toxicology and Bromatology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, dr. A. Jurasza 2, 85-089 Bydgoszcz, Poland
Robert Pluskota
Department of Toxicology and Bromatology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, dr. A. Jurasza 2, 85-089 Bydgoszcz, Poland
Katarzyna Mądra-Gackowska
Department of Geriatrics, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland, dr. A. Jurasza 2, 85-089 Bydgoszcz, Poland
Marcin Gackowski
Department of Toxicology and Bromatology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, dr. A. Jurasza 2, 85-089 Bydgoszcz, Poland
Michał J. Markuszewski
Department of Biopharmaceutics and Pharmacodynamics, Medical University of Gdańsk, al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland
Kornelia Kędziora-Kornatowska
Department of Geriatrics, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, Poland, dr. A. Jurasza 2, 85-089 Bydgoszcz, Poland
Marcin Koba
Department of Toxicology and Bromatology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, dr. A. Jurasza 2, 85-089 Bydgoszcz, Poland
Pterin compounds belong to the group of biomarkers for which an increase in interest has been observed in recent years. Available literature data point to this group of compounds as potential biomarkers for cancer detection, although the biochemical justification for this claim is not yet fully understood. The aim of this study was to evaluate the usefulness of pterin compounds in the diagnosis of bladder cancer, with particular emphasis on the role of creatinine and the specific gravity of urine as factors for normalizing the concentration of pterin compounds in urine. The standardization of the concentration of pterin compounds to urine specific gravity allows the building of better classification models for screening patients with potential cancer of the bladder. Of the compounds that make up the pterin profile, isoxanthopterin appears to be a compound that can potentially be described as a biomarker of bladder cancer.
